Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2024-08-13 Legal Proceedings Report
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
주요사항보고서(영업정지)
Legal Proceedings Report Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korea Exchange regarding a suspension of business operations (영업정지) due to regulatory administrative action (violation of pharmaceutical manufacturing standards). This is a specific regulatory disclosure required by the exchange for material events. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory filing, it falls under the 'Regulatory Filings' category.
2024-08-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of major shareholders (Cho Yong-joon and related parties) of DongKoo Bio & Pharma. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-06-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Correction Report). It details changes to previously granted stock options due to employee departures. This type of filing, which concerns changes in capital structure or equity-based compensation instruments, falls under the category of share/capital changes or regulatory filings. Given the specific nature of stock option grants and their impact on share capital, it is classified as a Share Issue/Capital Change announcement.
2024-05-23 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Dongkoo Bio&Pharma, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (pledges) of major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-05-03 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed by DongKoo Bio & Pharma Co., Ltd. with the Financial Supervisory Service (FSS) of South Korea. It details the termination of a trust agreement for the acquisition of treasury shares and the subsequent transfer of those shares to the company's own account. This type of filing is specifically related to the company's share repurchase program and its conclusion, which falls under the category of 'Transaction in Own Shares' (POS).
2024-05-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.